Target intelligence / Profile preview

Neurocan core protein (NCAN)

Target
NCAN
Molecular classification
Chondroitin sulfate proteoglycan (CSPG), Lectican family, Extracellular matrix protein
01

Overview

Neurocan core protein (NCAN) is a major extracellular matrix lectican/chondroitin sulfate proteoglycan predominantly found in the nervous system. It comprises a protein core and chondroitin sulfate glycosaminoglycan chains. Neurocan is a key regulator of neuronal growth, axon guidance, and inhibition of axonal regeneration following neural injury. Its expression is upregulated in the context of injury and implicated in suppressing neural differentiation, maintaining undifferentiated states, and inhibiting regeneration via interaction with protein tyrosine phosphatase receptor sigma (PTPRσ). High NCAN expression is associated with unfavorable outcomes in neuroblastoma and implicated in psychiatric disorders such as bipolar disorder, schizophrenia, and ADHD through gene variants. Neurocan interacts with other extracellular matrix components, including glypican-1, syndecan-3, and FGF2. Its role as a therapeutic target is supported primarily in the context of neuroblastoma and neural repair.

Other names
NeurocanCSPG3NEURChondroitin sulfate proteoglycan 3neurocan proteoglycanNCANneurocan core proteinchondroitin sulfate proteoglycan 3 (neurocan)
02

Mechanism of action

Inhibition of axon regeneration via activation of protein tyrosine phosphatase receptor sigma (PTPRσ); Promotion of undifferentiated phenotype and malignant transformation of neuroblastoma cells; Sequestration of HSPG co-receptors from FGFR1, suppressing cell differentiation

03

Biological functions

Inhibition of axon regenerationCell motility regulationCell differentiation and maintenance of neural stemnessNeuronal growth and neuroplasticityCell adhesionCell migration
04

Disease associations

Neuroblastoma (tumor malignancy, cancer)Psychiatric disorders (bipolar disorder, schizophrenia, ADHD)Neural injury (inhibition of regeneration)
05

Safety considerations

Inhibition of nerve regenerationPotential promotion of tumor growth/malignancy in neuroblastomaGenetic variants linked to psychiatric diseases
06

Biomarkers

NCAN expression as an unfavorable prognostic biomarker in neuroblastomaNCAN gene mutations/variants as biomarkers for psychiatric disorders

Beyond the preview

Go deeper on Neurocan core protein (NCAN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurocan core protein (NCAN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call